Impact on overall survival of radioactive iodine in low-risk differentiated thyroid cancer patients

Journal of Clinical Endocrinology and Metabolism

Volumn 97, Issue 5, 2012, Pages 1526-1535

  Schvartz, Claire ^a   Bonnetain, Franck ^c,d   Dabakuyo, Sandrine ^a,d   Gauthier, Melanie ^d   Cueff, Adele ^d   Fieffe, Sandrine ^b   Pochart, Jean Marie ^b   Cochet, Inna ^d   Crevisy, Elodie ^e   Dalac, Audrey ^a   Papathanassiou, Dimitri ^c   Toubeau, Michel ^d  

^a Department of Endocrinology and Nuclear Medicine   (France)

^b Thyroid Unit   (France)

^c INSTITUT JEAN GODINOT   (France)

^d CENTRE GEORGES FRANÇOIS LECLERC   (France)

^e DIJON UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

RADIOACTIVE IODINE;

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER RISK; CANCER SURVIVAL; CONTROLLED STUDY; DIFFERENTIATED THYROID CANCER; DISEASE FREE SURVIVAL; DISTANT METASTASIS; FEMALE; FOLLOW UP; HUMAN; LOCAL METASTASIS; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RADIATION DOSE; RADIOFREQUENCY ABLATION; SUBTOTAL THYROIDECTOMY; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA;

ADENOCARCINOMA, FOLLICULAR; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, PAPILLARY; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; SURVIVAL RATE; THYROID NEOPLASMS; TREATMENT OUTCOME;

EID: 84860479650     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2011-2512     Document Type: Article

References (29)

1. Sipos JA, Mazzaferri EL 2010 Thyroid cancer epidemiology and prognostic variables. Clin Oncol (R Coll Radiol) 22:395-404
2. Colonna M, Bossard N, Guizard AV, Remontet L, Grosclaude P, le réseau FRANCIM 2010 Descriptive epidemiology of thyroid cancers in France: incidence, mortality, survival. Ann Endocrinol (Paris) 71:95-101
3. Cooper DS, Doherty GM, Haugen BR, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM 2009 Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19:1167-1214
4. Pacin IF, Schlumberge RM, Drall EH, Elise IR, Smit JW, Wiersinga W; European Thyroid Cancer Taskforce 2006 European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 154:787-803
5. Samaan NA, Schultz PN, Hickey RC, Goepfer TH, Haynie TP, Johnston DA, Ordonez NG 1992 The results of various modalities of treatment of well differentiated thyroid carcinomas: a retrospective review of 1599 patients. J Clin Endocrinol Metab 75:714-720
6. Shaha AR, Shah JP, Loree TR 1997 Low-risk differentiated thyroid cancer: the need for selective treatment. Ann Surg Oncol 4:328-333
7. Sanders LE, Cady B 1998 Differentiated thyroid cancer: reexamination of risk groups and outcome of treatment. Arch Surg 133:419-425
8. Morris DM, Boyle PJ, Stidley CA, Altobelli KK, Parnell T, Key C 1998 Localized well-differentiated thyroid carcinoma: a survival analysis of prognostic factors and 131 I therapy. Ann Surg Oncol 5:329-337
9. Saadi H, Kleidermacher P, Esselstyn Jr C 2001 Conservative management ofpatients with intrathyroidal well-differentiated follicular carcinoma. Surgery 130:30-35
10. Greene FL, Page DL, Fleming ID, April F 2002 AJCC/UICC cancer staging handbook: TNM classification of malignant tumors. 6th ed. New York: Springer-Verlag
11. Rosenbaum PR, Rubin DB 1983 The central role of the propensity score in observational studies for causal effects. Biometrika 70:41-55
12. Austin PC 2008 The performance of different propensity-score methods for estimating relative risks. J Clin Epidemiol 61:537-545
13. D'Agostino RB 1998 Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 17:2265-2281
14. Sack SW, Fung CH, Chang JT, Waxma NA, Braunstein GD 2010 The effectiveness of radioactive iodine for treatment of low risk thyroid cancer: a systematic analysis of the peer reviewed literature from 1966 to April 2008. Thyroid 20:1235-1245
15. Hundahl SA, Fleming ID, Fremgen AM, Menck HR 1998 A National Cancer Data Base report on 53, 856 cases of thyroid carcinoma treated in the U. S., 1985-1995. Cancer 83:2638-2648
16. Tuttle RM, Tala H, Shah J, Leboeuf R, Ghossein R, Gonen M, Brokhin M, Omry G, Fagin JA, Shaha A 2010 Estimating risk of recurrencein differentiated thyroid cancer after total thyroidectomy and radioactive iodine ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association system. Thyroid 20:1341-1349
17. Hay ID, McConahey WM, Goellner JR 2002 Managing patients with papillary thyroid carcinoma: insights gained from the Mayo Clinic's experience of treating 2512 consecutive patients during 1940 through 2000. Trans Am Clin Climatol Assoc 113:241-260
18. Sawka AM, Thephamongkhol K, Brouwers M, Thabane L, Browman G, Gerstein HC 2004 Clinical review 170: a systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J Clin Endocrinol Metab 89:3668-3676
19. Podnos YD, Smith DD, Wagman LD, Ellenhorn JD 2007 Survival in patients with papillary thyroid cancer is not affected by the use of radioactive isotope. J Surg Oncol 96:3-7
20. Jonklaas J, Sarlis NJ, Litofsky D, Ain KB, Bigos ST, Brierley JD, Cooper DS, Haugen BR, Ladenson PW, Magner J, Robbins J, Ross DS, Skaruli SM, Maxon HR, Sherman SI 2006 Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid 16:1229-1242
21. Jonklaas J, Cooper DS, Ain KB, Bigos T, Brierley JD, Haugen BR, Ladenson PW, Magner J, Ross DS, Skarulis MC, Steward DL, Maxon HR, Sherman SI; National Thyroid Cancer Treatment Cooperative Study Group 2010 Radioiodine therapy in patients with stage I differentiated thyroid cancer. Thyroid 20:1423-1424
22. Albores-Saavedra J, Wu J 2006 The many faces and mimics of papillary thyroid carcinoma. Endocr Pathol 17:1-18
23. Lloyd RV, Erickson LA, Casey MB, Lam KY, Lohse CM, Asa SL, Chan JK, De Lellis RA, Harach HR, Kakudo K, Li Volsi VA, Rosai J, Sebo TJ, Sobrinho-Simoe SM, Wenig BM, Lae ME 2004 Observer variation in the diagnosis of follicular variant of papillary thyroid carcinoma. Am J Surg Pathol 28:1336-1340
24. Franc B, de la Salmonière P, Lange F, Hoang C, Louvel A, de Roquancourt A, Vildé F, Hejblum G, Chevret S, Chastang C 2003 Interobserver and intraobserver reproducibility in the histopathology of follicular thyroid carcinoma. Hum Pathol 34:1092-1100
25. Mazzaferri EL, Young RL 1981 Papillary thyroid carcinoma: a 10 year follow-up report of the impact of therapy in 576 patients. Am J Med 70:511-518
26. Brierley J, Tsang R, Panzarella T, Bana N 2005 Prognostic factors and the effect of treatment with radioactive iodine and external beam radiation on patients with differentiated thyroid cancer seen at a single institution over 40 years. Clin Endocrinol (Oxf) 63:418-427
27. Sawka AM, Brierley JD, Tsang RW, Thabane L, Rotstein L, Gafni A, Straus S, Goldstein DP 2008 An updated systematic review and commentary examining the effectiveness of radioactive iodine remnant ablation in well differentiated thyroid cancer. Endocrinol Metab Clin North Am 37:457-480, x
28. Hay ID 2007 Management of patients with low-risk papillary thyroid carcinoma. Endocr Pract 13:521-533
29. Beitz J, Gnecco C, Justice R 1996 Quality-of-life end points in cancer clinical trials: the U. S. Food and Drug Administration perspective. J Natl Cancer Inst Monogr 1996:7-9